News|Articles|February 1, 2012

Pharmaceutical Technology Europe

  • Pharmaceutical Technology Europe-02-01-2012
  • Volume 24
  • Issue 2

Evaluating Impurities in Drugs (Part I of III)

In Part I of a three-part article, the authors discuss what constitutes an impurity and the potential sources of impurities in APIs and finished drug products.

By Kashyap R. Wadekar, Mitali Bhalme, S. Srinivasa Rao, K. Vigneshwar Reddy, L. Sampath Kumar and E. Balasubrahmanyam

To ensure the quality of APIs and finished drug products, impurities must be monitored carefully during process development, optimization, and process changeover. The isolation, characterization, and control of impurities in pharmaceutical substances are being reviewed with greater attention based on national regulatory and international guidelines. In Part I of this article, the authors examine the different types and sources of impurities with specific examples.

This article was also published in our US sister publication Pharmaceutical Technology and can be read here.

Articles in this issue

almost 15 years ago

News: FDA's Social Media Insight

almost 15 years ago

Head in the Clouds

almost 15 years ago

Cliffhanger

almost 15 years ago

Understanding Gamma Sterilisation

Related to this article

AAPS PharmSci 360 2026: Spray Drying and ASD
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF, talks about spray drying for drying amorphous solid dispersions and Raman spectroscopy’s role as a quantitative analytical tool.
AAPS PharmSci 360 2026: High-Loaded ASD
Nitin Kumar Swarnakar, PhD, global application lab manager at BASF in Tarrytown, spoke with PharmTech at AAPS PharmSci 360 about formulation and characterization challenges for amorphous solid dispersions.